Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4585124
Max Phase: Preclinical
Molecular Formula: C70H109N17O12
Molecular Weight: 1380.75
Molecule Type: Unknown
Associated Items:
ID: ALA4585124
Max Phase: Preclinical
Molecular Formula: C70H109N17O12
Molecular Weight: 1380.75
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)N(C)C(=O)[C@H](N)CCCCN)C(C)C)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)O
Standard InChI: InChI=1S/C70H109N17O12/c1-8-43(6)59(67(96)83-55(39-46-40-78-50-25-13-12-23-48(46)50)62(91)79-51(26-15-18-34-72)60(89)80-52(69(98)99)27-16-19-35-73)86-66(95)58(42(4)5)85-65(94)57(41(2)3)84-63(92)54(38-45-29-31-47(88)32-30-45)81-61(90)53(37-44-21-10-9-11-22-44)82-64(93)56(28-20-36-77-70(75)76)87(7)68(97)49(74)24-14-17-33-71/h9-13,21-23,25,29-32,40-43,49,51-59,78,88H,8,14-20,24,26-28,33-39,71-74H2,1-7H3,(H,79,91)(H,80,89)(H,81,90)(H,82,93)(H,83,96)(H,84,92)(H,85,94)(H,86,95)(H,98,99)(H4,75,76,77)/t43-,49+,51-,52+,53-,54-,55-,56-,57-,58-,59-/m0/s1
Standard InChI Key: UPIDRVVFNIKDQA-KVPZATETSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1380.75 | Molecular Weight (Monoisotopic): 1379.8442 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Denèfle T, Pramil E, Gómez-Morales L, Levasseur MD, Lardé E, Newton C, Herry K, Herbi L, Lamotte Y, Odile E, Ancellin N, Grondin P, Martinez-Torres AC, Viviani F, Merle-Beral H, Lequin O, Susin SA, Karoyan P.. (2019) Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells., 62 (17): [PMID:31403795] [10.1021/acs.jmedchem.9b00024] |
Source(1):